# Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)

> **NCT03888729** · PHASE4 · UNKNOWN · sponsor: **Partners in Health** · enrollment: 100 (estimated)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** sofosbubir/velpatasvir
- **DRUG:** sofosbubir/velpatasvir/voxilaprevir

## Key facts

- **NCT ID:** NCT03888729
- **Lead sponsor:** Partners in Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-26
- **Primary completion:** 2020-03
- **Final completion:** 2020-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2019-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03888729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03888729, "Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT03888729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*